Skip to main content
Homepage
PARTIAL Analysis Report
Sep 4, 2026
58 days ago · 2% complete
Partial analysis — no complete end-to-end run on record.
No report run on this ticker yet Only preliminary foundational data below
NOT YET RESEARCHED No report has been run on MNKD yet. What you are seeing is foundational data only — price, profile and filings — not the full analysis (lenses, memo, scores and the AI panel arrive with the first report).
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for MannKind Corporation (MNKD) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at voiceoftrades.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

MannKind Corporation

MNKD NASDAQ
Healthcare · Biotechnology
Danbury, CT 06810, United States mannkindcorp.com Updated Nov 2, 1:56am
Price
$3.92
Market Cap
$1.3B
Employees
591
Beta
1.10
Avg Volume
4,157,040
CEO
Dr. Michael E. Castagna Pharm.D.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.

Runs with full report
Price Overview
Current data · timestamped when a report runs
$3.57
Change
-0.18 (-4.80%)
Day Range
$3.54 – $3.75
52-Week Range
$2.23 – $6.51
50-Day MA
$3.99
200-Day MA
$4.12
Volume
233,412.00
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 1 computed · 6 not applicable · 17 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MNKD — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for MNKD — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for MNKD — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for MNKD — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for MNKD. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this